Company · Public · IONS
Ionis Pharmaceuticals, Inc.
RNA-targeted medicines company whose antisense platform discovered diranersen (IONIS-MAPTRx / BIIB080), a MAPT-directed antisense oligonucleotide for Alzheimer's disease; Biogen exercised its licence option and holds a worldwide exclusive royalty-bearing licence to develop and commercialise it.
Listing
Public
Ticker
IONS
Headquarters
—
Founded
—
Technology
Antisense oligonucleotide (ASO)
Category
Longevity thesis
Antisense discovery against a defined mRNA target lets one platform address age-associated proteinopathies it does not itself take through late clinical development.
Programmes
- Diranersen (discovered by Ionis; licensed to Biogen)Not curated
Alzheimer's disease
Reference information for research context only. It is not a rating, a valuation or investment advice. Published developments appear in the News archive.